Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. (Q54065301)

24 May 2018

title

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. (English)

1 reference

24 May 2018

1 reference

van der Flier S

1

1 reference

24 May 2018

Brinkman A

2

1 reference

24 May 2018

Look MP

3

1 reference

24 May 2018

Kok EM

4

1 reference

24 May 2018

Meijer-van Gelder ME

5

1 reference

24 May 2018

Klijn JG

6

1 reference

24 May 2018

Dorssers LC

7

1 reference

24 May 2018

Foekens JA

8

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 January 2000

1 reference

24 May 2018

Journal of the National Cancer Institute

published in

1 reference

24 May 2018

volume

92

1 reference

24 May 2018

issue

2

1 reference

24 May 2018

page(s)

120-127

1 reference

24 May 2018

The nuclear receptor superfamily: the second decade

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Increasing the complexity of coactivation in nuclear receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Cloning of a novel receptor expressed in rat prostate and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

ER beta: identification and characterization of a novel human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Mechanisms of hormone resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

A novel estrogen receptor variant mRNA lacking exons 4 to 6 in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Oestrogen receptor mutants and variants in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Complexes of focal adhesion kinase (FAK) and Crk-associated substrate (p130(Cas)) are elevated in cytoskeleton-associated fractions following adhesion and Src transformation. Requirements for Src kinase activity and FAK proline-rich motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

CAS/Crk coupling serves as a "molecular switch" for induction of cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Epidermal growth factor modulates tyrosine phosphorylation of p130Cas. Involvement of phosphatidylinositol 3'-kinase and actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Use of tamoxifen for breast cancer: twenty-eight years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F92.2.120

21 January 2018

Identifiers

DOI

10.1093/JNCI/92.2.120

1 reference

24 May 2018

PubMed ID

10639513

1 reference

24 May 2018